Report
Drug discovery in Q3 2026: AI, virtual screening and molecular glues
Drug Target Review examines these developments alongside human-relevant models and what to watch heading into Q4.
TLDR
Drug Target Review highlights agentic AI, ultralarge virtual screening, molecular glues and human-relevant models among the key developments in early drug discovery during Q3 2026. Its overview also looks ahead to Q4.
Combined views
365
1 Source, first seen ago